Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cancer Vaccines | 34 | 2023 | 1042 | 7.370 |
Why?
|
Dendritic Cells | 43 | 2023 | 2748 | 3.930 |
Why?
|
Multiple Myeloma | 50 | 2024 | 5195 | 3.900 |
Why?
|
Mucin-1 | 21 | 2017 | 539 | 3.840 |
Why?
|
Immunotherapy | 22 | 2023 | 4755 | 2.060 |
Why?
|
Hematologic Neoplasms | 15 | 2024 | 1907 | 1.980 |
Why?
|
Hematopoietic Stem Cell Transplantation | 32 | 2024 | 5716 | 1.560 |
Why?
|
Leukemia, Myeloid, Acute | 15 | 2022 | 3626 | 1.460 |
Why?
|
Immunotherapy, Active | 3 | 2018 | 58 | 1.440 |
Why?
|
Immunotherapy, Adoptive | 14 | 2023 | 1519 | 1.200 |
Why?
|
Azacitidine | 3 | 2019 | 336 | 1.090 |
Why?
|
Cell Fusion | 12 | 2012 | 294 | 0.920 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 209 | 0.900 |
Why?
|
Vaccination | 13 | 2023 | 3436 | 0.870 |
Why?
|
Graft vs Host Disease | 16 | 2024 | 3048 | 0.850 |
Why?
|
Antigens, Neoplasm | 8 | 2021 | 2001 | 0.820 |
Why?
|
T-Lymphocytes | 19 | 2021 | 10276 | 0.810 |
Why?
|
Thalidomide | 5 | 2017 | 886 | 0.720 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 22 | 2024 | 11886 | 0.710 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2023 | 892 | 0.690 |
Why?
|
Dexamethasone | 6 | 2024 | 1965 | 0.660 |
Why?
|
Stem Cell Transplantation | 9 | 2018 | 1602 | 0.660 |
Why?
|
Lymphocyte Activation | 19 | 2022 | 5505 | 0.650 |
Why?
|
Tumor Microenvironment | 9 | 2023 | 3951 | 0.650 |
Why?
|
Immunomodulation | 4 | 2018 | 549 | 0.640 |
Why?
|
Antibodies, Monoclonal | 14 | 2024 | 9264 | 0.620 |
Why?
|
Cell Proliferation | 17 | 2020 | 10486 | 0.620 |
Why?
|
Transplantation Conditioning | 7 | 2020 | 1601 | 0.610 |
Why?
|
Transplantation, Autologous | 13 | 2023 | 2126 | 0.600 |
Why?
|
Transplantation, Homologous | 12 | 2024 | 4835 | 0.590 |
Why?
|
T-Lymphocytes, Regulatory | 10 | 2017 | 3116 | 0.580 |
Why?
|
Interleukin-12 | 4 | 2008 | 577 | 0.560 |
Why?
|
Remission Induction | 9 | 2017 | 2411 | 0.540 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2017 | 658 | 0.540 |
Why?
|
Peptides | 6 | 2017 | 4353 | 0.510 |
Why?
|
Melphalan | 5 | 2019 | 421 | 0.480 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2019 | 305 | 0.470 |
Why?
|
Immunity, Cellular | 5 | 2019 | 1560 | 0.460 |
Why?
|
Immune Tolerance | 4 | 2018 | 2323 | 0.460 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 283 | 0.460 |
Why?
|
Lymphoma, B-Cell | 4 | 2021 | 945 | 0.440 |
Why?
|
Cell Communication | 4 | 2017 | 1660 | 0.440 |
Why?
|
Molecular Targeted Therapy | 5 | 2018 | 2830 | 0.420 |
Why?
|
Antigens, CD34 | 6 | 2024 | 656 | 0.410 |
Why?
|
Humans | 154 | 2024 | 768887 | 0.410 |
Why?
|
Antigen Presentation | 7 | 2012 | 1252 | 0.400 |
Why?
|
Apoptosis | 11 | 2020 | 9528 | 0.400 |
Why?
|
Coculture Techniques | 7 | 2017 | 1342 | 0.400 |
Why?
|
Lymphocyte Transfusion | 2 | 2014 | 232 | 0.390 |
Why?
|
Bone Marrow | 3 | 2023 | 2935 | 0.390 |
Why?
|
Recurrence | 12 | 2023 | 8512 | 0.390 |
Why?
|
Oligonucleotides | 2 | 2020 | 563 | 0.390 |
Why?
|
CD8-Positive T-Lymphocytes | 5 | 2022 | 4651 | 0.370 |
Why?
|
MicroRNAs | 5 | 2020 | 3811 | 0.370 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2012 | 1803 | 0.370 |
Why?
|
Stromal Cells | 1 | 2017 | 1337 | 0.370 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 338 | 0.370 |
Why?
|
Antigens, CD | 5 | 2016 | 4032 | 0.370 |
Why?
|
Cell Line, Tumor | 18 | 2020 | 17174 | 0.370 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2015 | 1151 | 0.360 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2007 | 631 | 0.360 |
Why?
|
Leukocytes, Mononuclear | 4 | 2017 | 1855 | 0.330 |
Why?
|
Oxidative Stress | 3 | 2017 | 3138 | 0.330 |
Why?
|
Cytotoxicity, Immunologic | 7 | 2017 | 1356 | 0.310 |
Why?
|
Granzymes | 1 | 2010 | 278 | 0.300 |
Why?
|
Antineoplastic Agents | 13 | 2017 | 13699 | 0.300 |
Why?
|
Reactive Oxygen Species | 6 | 2017 | 2149 | 0.300 |
Why?
|
Virus Activation | 3 | 2019 | 324 | 0.290 |
Why?
|
Animals | 33 | 2022 | 169408 | 0.290 |
Why?
|
Neoplastic Stem Cells | 2 | 2013 | 1356 | 0.290 |
Why?
|
Interferon-gamma | 6 | 2017 | 3163 | 0.280 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2020 | 1437 | 0.270 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 921 | 0.270 |
Why?
|
Transplantation Immunology | 3 | 2016 | 537 | 0.270 |
Why?
|
Kidney Neoplasms | 5 | 2007 | 4300 | 0.270 |
Why?
|
Immunologic Factors | 3 | 2018 | 1597 | 0.270 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2007 | 225 | 0.260 |
Why?
|
Killer Cells, Natural | 6 | 2016 | 2211 | 0.260 |
Why?
|
Th17 Cells | 1 | 2012 | 791 | 0.260 |
Why?
|
Flow Cytometry | 10 | 2015 | 5905 | 0.250 |
Why?
|
Tumor Cells, Cultured | 12 | 2019 | 6131 | 0.250 |
Why?
|
Immunophenotyping | 10 | 2013 | 1866 | 0.250 |
Why?
|
Breast Neoplasms | 14 | 2017 | 21187 | 0.250 |
Why?
|
Leukemia | 4 | 2016 | 1520 | 0.240 |
Why?
|
Neoplasms | 8 | 2016 | 22390 | 0.240 |
Why?
|
Pancreatic Neoplasms | 1 | 2022 | 5443 | 0.230 |
Why?
|
Anilides | 2 | 2017 | 414 | 0.230 |
Why?
|
Boronic Acids | 4 | 2014 | 915 | 0.220 |
Why?
|
B-Cell Maturation Antigen | 2 | 2022 | 149 | 0.220 |
Why?
|
Mice | 21 | 2022 | 82074 | 0.210 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2020 | 8664 | 0.210 |
Why?
|
Drug Synergism | 6 | 2017 | 1762 | 0.210 |
Why?
|
Signal Transduction | 6 | 2017 | 23652 | 0.210 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 1705 | 0.210 |
Why?
|
Whole-Body Irradiation | 2 | 2020 | 435 | 0.200 |
Why?
|
Carcinoma, Renal Cell | 3 | 2007 | 3200 | 0.200 |
Why?
|
Th1-Th2 Balance | 2 | 2012 | 38 | 0.200 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 133 | 0.200 |
Why?
|
Pyrazines | 4 | 2014 | 1206 | 0.200 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2017 | 494 | 0.200 |
Why?
|
Immune System | 2 | 2018 | 800 | 0.190 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 3714 | 0.190 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 696 | 0.190 |
Why?
|
Down-Regulation | 3 | 2019 | 2941 | 0.190 |
Why?
|
Cryptosporidiosis | 1 | 2021 | 52 | 0.180 |
Why?
|
Mice, SCID | 3 | 2016 | 2631 | 0.180 |
Why?
|
Oncogene Proteins | 2 | 2016 | 718 | 0.180 |
Why?
|
Hodgkin Disease | 3 | 2019 | 1384 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2017 | 998 | 0.180 |
Why?
|
Cell Differentiation | 10 | 2017 | 11684 | 0.180 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1376 | 0.170 |
Why?
|
Photopheresis | 1 | 2020 | 35 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2020 | 3621 | 0.170 |
Why?
|
Oligopeptides | 2 | 2024 | 1194 | 0.170 |
Why?
|
Biomedical Research | 3 | 2010 | 3463 | 0.170 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1839 | 0.170 |
Why?
|
Vitamin D | 2 | 2012 | 3311 | 0.170 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 686 | 0.170 |
Why?
|
Blotting, Western | 4 | 2015 | 5035 | 0.170 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 4593 | 0.170 |
Why?
|
Middle Aged | 51 | 2024 | 223740 | 0.170 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1019 | 0.160 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 330 | 0.160 |
Why?
|
Hematopoietic Stem Cells | 6 | 2013 | 3408 | 0.160 |
Why?
|
Lymphocyte Culture Test, Mixed | 6 | 2009 | 510 | 0.160 |
Why?
|
Isoantigens | 2 | 2017 | 562 | 0.160 |
Why?
|
Female | 60 | 2024 | 397464 | 0.160 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 302 | 0.160 |
Why?
|
Cytarabine | 3 | 2019 | 697 | 0.150 |
Why?
|
Interleukin-2 | 3 | 2016 | 1895 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 640 | 0.150 |
Why?
|
Oligonucleotides, Antisense | 1 | 2020 | 461 | 0.150 |
Why?
|
Oxidation-Reduction | 4 | 2017 | 2226 | 0.150 |
Why?
|
Vinblastine | 1 | 2019 | 487 | 0.150 |
Why?
|
Lymphoma | 5 | 2020 | 1900 | 0.150 |
Why?
|
Herpesvirus 6, Human | 1 | 2018 | 98 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.150 |
Why?
|
Forkhead Transcription Factors | 4 | 2017 | 1625 | 0.140 |
Why?
|
Aged | 36 | 2024 | 171790 | 0.140 |
Why?
|
Cross-Priming | 1 | 2017 | 75 | 0.140 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2018 | 158 | 0.140 |
Why?
|
Perforin | 1 | 2017 | 167 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2017 | 5342 | 0.140 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2019 | 249 | 0.140 |
Why?
|
Glutathione | 3 | 2015 | 589 | 0.140 |
Why?
|
Myelodysplastic Syndromes | 2 | 2020 | 1399 | 0.140 |
Why?
|
Fusion Proteins, bcr-abl | 2 | 2010 | 430 | 0.140 |
Why?
|
Adult | 45 | 2024 | 223818 | 0.140 |
Why?
|
Male | 50 | 2024 | 365249 | 0.140 |
Why?
|
Receptors, CCR7 | 2 | 2008 | 105 | 0.140 |
Why?
|
Galactosylceramides | 1 | 2017 | 90 | 0.140 |
Why?
|
JC Virus | 2 | 2014 | 87 | 0.140 |
Why?
|
Mitoxantrone | 3 | 2017 | 148 | 0.130 |
Why?
|
Retroviridae | 1 | 2019 | 849 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2017 | 287 | 0.130 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 1998 | 264 | 0.130 |
Why?
|
Dacarbazine | 1 | 2019 | 559 | 0.130 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2015 | 414 | 0.130 |
Why?
|
Tretinoin | 1 | 2019 | 525 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5864 | 0.130 |
Why?
|
Polydeoxyribonucleotides | 2 | 2010 | 136 | 0.130 |
Why?
|
HMGB1 Protein | 1 | 2017 | 141 | 0.130 |
Why?
|
Cell Survival | 5 | 2016 | 5794 | 0.120 |
Why?
|
Bone Marrow Transplantation | 3 | 2017 | 2709 | 0.120 |
Why?
|
Glioblastoma | 2 | 2023 | 3525 | 0.120 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
Pyridines | 2 | 2017 | 2896 | 0.120 |
Why?
|
Ribonuclease III | 1 | 2017 | 271 | 0.120 |
Why?
|
Doxorubicin | 4 | 2019 | 2234 | 0.120 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2018 | 0.120 |
Why?
|
Etoposide | 3 | 2017 | 639 | 0.120 |
Why?
|
Tumor Escape | 1 | 2018 | 372 | 0.120 |
Why?
|
Chemokine CXCL12 | 1 | 2017 | 457 | 0.120 |
Why?
|
Gene Silencing | 3 | 2017 | 1505 | 0.120 |
Why?
|
Immunoblotting | 3 | 2014 | 1647 | 0.120 |
Why?
|
Hybrid Cells | 2 | 2005 | 421 | 0.120 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2010 | 220 | 0.120 |
Why?
|
Virus Diseases | 1 | 2001 | 724 | 0.120 |
Why?
|
Antigen-Presenting Cells | 1 | 2018 | 962 | 0.120 |
Why?
|
Response Elements | 1 | 2016 | 308 | 0.120 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2892 | 0.120 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2016 | 534 | 0.120 |
Why?
|
Graft vs Leukemia Effect | 1 | 2014 | 121 | 0.110 |
Why?
|
NADP | 1 | 2015 | 230 | 0.110 |
Why?
|
Transplantation | 1 | 2015 | 221 | 0.110 |
Why?
|
Yttrium Radioisotopes | 1 | 2015 | 114 | 0.110 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 306 | 0.110 |
Why?
|
Lymphoma, T-Cell | 1 | 2016 | 308 | 0.110 |
Why?
|
Fetal Blood | 2 | 2019 | 1360 | 0.110 |
Why?
|
Treatment Outcome | 19 | 2024 | 65485 | 0.110 |
Why?
|
Cells, Cultured | 7 | 2014 | 19023 | 0.110 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 560 | 0.110 |
Why?
|
Antigens, CD1 | 3 | 2008 | 434 | 0.110 |
Why?
|
Leukapheresis | 3 | 2003 | 150 | 0.110 |
Why?
|
Interleukin-10 | 3 | 2009 | 1184 | 0.110 |
Why?
|
Necrosis | 2 | 2015 | 1621 | 0.110 |
Why?
|
Parathyroid Hormone | 2 | 2012 | 1803 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 778 | 0.110 |
Why?
|
Fowlpox virus | 1 | 2012 | 21 | 0.100 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2019 | 958 | 0.100 |
Why?
|
PPAR delta | 1 | 2012 | 40 | 0.100 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1082 | 0.100 |
Why?
|
STAT3 Transcription Factor | 1 | 2017 | 875 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2001 | 1397 | 0.100 |
Why?
|
Arabinonucleosides | 1 | 2012 | 34 | 0.100 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 3 | 2003 | 263 | 0.100 |
Why?
|
Adenine Nucleotides | 1 | 2012 | 110 | 0.100 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 300 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 3 | 2012 | 1813 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 617 | 0.100 |
Why?
|
STAT Transcription Factors | 1 | 2012 | 189 | 0.100 |
Why?
|
Ifosfamide | 2 | 2003 | 233 | 0.100 |
Why?
|
Interleukin-4 | 3 | 2014 | 1157 | 0.100 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 151 | 0.090 |
Why?
|
Combined Modality Therapy | 6 | 2016 | 8559 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2021 | 2574 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1120 | 0.090 |
Why?
|
Hematologic Diseases | 2 | 2012 | 498 | 0.090 |
Why?
|
Transcriptional Activation | 1 | 2017 | 1750 | 0.090 |
Why?
|
Viral Proteins | 1 | 2018 | 1802 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2017 | 641 | 0.090 |
Why?
|
RNA, Messenger | 3 | 2015 | 12809 | 0.090 |
Why?
|
Lymphocyte Depletion | 2 | 2006 | 605 | 0.090 |
Why?
|
Cytokines | 3 | 2017 | 7453 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 2 | 2012 | 2813 | 0.090 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 70 | 0.090 |
Why?
|
Radiotherapy | 1 | 2017 | 1506 | 0.080 |
Why?
|
Pyrimidines | 2 | 2019 | 3050 | 0.080 |
Why?
|
Survival Analysis | 7 | 2019 | 10115 | 0.080 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 355 | 0.080 |
Why?
|
Mitogens | 1 | 2010 | 229 | 0.080 |
Why?
|
Sirolimus | 1 | 2017 | 1540 | 0.080 |
Why?
|
Chromosome Aberrations | 1 | 2016 | 1780 | 0.080 |
Why?
|
Transduction, Genetic | 1 | 2012 | 902 | 0.080 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 251 | 0.080 |
Why?
|
Multiple Organ Failure | 2 | 2010 | 387 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2017 | 1203 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2023 | 9213 | 0.080 |
Why?
|
Maximum Tolerated Dose | 3 | 2017 | 899 | 0.080 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 315 | 0.080 |
Why?
|
Cell Division | 3 | 2012 | 4478 | 0.080 |
Why?
|
Up-Regulation | 1 | 2017 | 4148 | 0.070 |
Why?
|
Mice, Inbred C57BL | 5 | 2019 | 22381 | 0.070 |
Why?
|
Cell Separation | 3 | 2016 | 1728 | 0.070 |
Why?
|
Metabolic Networks and Pathways | 1 | 2012 | 800 | 0.070 |
Why?
|
Survival Rate | 8 | 2015 | 12873 | 0.070 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2005 | 317 | 0.070 |
Why?
|
Receptors, Immunologic | 1 | 2014 | 1418 | 0.070 |
Why?
|
DNA Methylation | 2 | 2019 | 4432 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2012 | 4413 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9442 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2525 | 0.070 |
Why?
|
Fibrinolytic Agents | 2 | 2010 | 2080 | 0.070 |
Why?
|
Disease-Free Survival | 7 | 2015 | 6856 | 0.070 |
Why?
|
Isocoumarins | 1 | 2006 | 21 | 0.070 |
Why?
|
Authorship | 1 | 2010 | 289 | 0.070 |
Why?
|
Antimitotic Agents | 1 | 2006 | 28 | 0.070 |
Why?
|
Cell Polarity | 1 | 2010 | 639 | 0.070 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18366 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2960 | 0.070 |
Why?
|
Clone Cells | 1 | 2010 | 1670 | 0.070 |
Why?
|
Filgrastim | 2 | 2007 | 131 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2012 | 5803 | 0.060 |
Why?
|
Immunocompromised Host | 2 | 2021 | 865 | 0.060 |
Why?
|
Young Adult | 12 | 2024 | 60110 | 0.060 |
Why?
|
Chronic Disease | 5 | 2023 | 9384 | 0.060 |
Why?
|
Granulocyte Precursor Cells | 1 | 2004 | 49 | 0.060 |
Why?
|
Bone Marrow Cells | 3 | 2004 | 2414 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4207 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 555 | 0.060 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1642 | 0.060 |
Why?
|
Lymphocyte Count | 3 | 2016 | 793 | 0.060 |
Why?
|
Fatty Acids | 1 | 2012 | 1812 | 0.060 |
Why?
|
Interleukin-7 | 1 | 2005 | 146 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5707 | 0.060 |
Why?
|
Tissue Donors | 3 | 2018 | 2382 | 0.060 |
Why?
|
Gene Expression | 1 | 2017 | 7602 | 0.060 |
Why?
|
Disclosure | 1 | 2010 | 754 | 0.060 |
Why?
|
Neoplasms, Experimental | 2 | 2019 | 1231 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2014 | 3233 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6546 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10397 | 0.050 |
Why?
|
Aged, 80 and over | 9 | 2021 | 59738 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2848 | 0.050 |
Why?
|
Drug Industry | 1 | 2010 | 793 | 0.050 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2009 | 716 | 0.050 |
Why?
|
Case-Control Studies | 4 | 2015 | 22294 | 0.050 |
Why?
|
Clinical Trials as Topic | 4 | 2014 | 8055 | 0.050 |
Why?
|
Antibody Formation | 2 | 2005 | 1393 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1042 | 0.050 |
Why?
|
Genetic Vectors | 1 | 2012 | 3414 | 0.050 |
Why?
|
Glucocorticoids | 4 | 2018 | 2167 | 0.050 |
Why?
|
Drug Administration Schedule | 5 | 2013 | 4862 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2005 | 652 | 0.050 |
Why?
|
Sterilization | 1 | 2003 | 132 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7609 | 0.050 |
Why?
|
Lymphocytes | 2 | 2023 | 2614 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 414 | 0.050 |
Why?
|
Mitosis | 1 | 2006 | 1181 | 0.050 |
Why?
|
Pentostatin | 1 | 2020 | 26 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4528 | 0.050 |
Why?
|
K562 Cells | 3 | 2010 | 648 | 0.050 |
Why?
|
Transcription Factors | 2 | 2012 | 12174 | 0.040 |
Why?
|
Mice, Inbred BALB C | 4 | 2013 | 6232 | 0.040 |
Why?
|
Phytohemagglutinins | 1 | 2000 | 165 | 0.040 |
Why?
|
Pancreatitis | 1 | 2007 | 1087 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2000 | 114 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2011 | 2100 | 0.040 |
Why?
|
Antibodies | 1 | 2008 | 2422 | 0.040 |
Why?
|
Idarubicin | 1 | 2019 | 59 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2002 | 619 | 0.040 |
Why?
|
Salvage Therapy | 2 | 2017 | 1277 | 0.040 |
Why?
|
Hypersensitivity, Delayed | 1 | 2000 | 491 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39394 | 0.040 |
Why?
|
Prednisone | 2 | 2018 | 1567 | 0.040 |
Why?
|
U937 Cells | 1 | 2019 | 260 | 0.040 |
Why?
|
Foscarnet | 1 | 2018 | 36 | 0.040 |
Why?
|
Periodicals as Topic | 1 | 2010 | 1470 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2021 | 446 | 0.040 |
Why?
|
Bacterial Vaccines | 1 | 2001 | 400 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2019 | 9564 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 2 | 2013 | 2475 | 0.040 |
Why?
|
Vidarabine | 1 | 2019 | 337 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2001 | 593 | 0.040 |
Why?
|
Skin Tests | 1 | 2000 | 639 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 938 | 0.040 |
Why?
|
Contrast Media | 1 | 2011 | 5334 | 0.040 |
Why?
|
Cyclosporine | 1 | 2020 | 777 | 0.040 |
Why?
|
Models, Biological | 2 | 2012 | 9499 | 0.040 |
Why?
|
Thrombopoietin | 1 | 2019 | 226 | 0.040 |
Why?
|
Treatment Failure | 2 | 2020 | 2663 | 0.040 |
Why?
|
Chimerism | 1 | 2018 | 156 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2931 | 0.030 |
Why?
|
Herpesvirus 8, Human | 1 | 1999 | 256 | 0.030 |
Why?
|
Methotrexate | 2 | 2020 | 1723 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2000 | 855 | 0.030 |
Why?
|
Heartburn | 1 | 2017 | 71 | 0.030 |
Why?
|
Glutamate-Cysteine Ligase | 1 | 2016 | 23 | 0.030 |
Why?
|
Tacrolimus | 1 | 2020 | 750 | 0.030 |
Why?
|
Mutation | 2 | 2019 | 30266 | 0.030 |
Why?
|
Th2 Cells | 1 | 2001 | 1079 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6512 | 0.030 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2016 | 103 | 0.030 |
Why?
|
Cyclin D2 | 1 | 2016 | 98 | 0.030 |
Why?
|
Protein Binding | 1 | 2008 | 9344 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9618 | 0.030 |
Why?
|
Benzylamines | 1 | 2017 | 251 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 245 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3744 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 10778 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 272 | 0.030 |
Why?
|
Phenotype | 3 | 2011 | 16735 | 0.030 |
Why?
|
Viral Vaccines | 1 | 2001 | 596 | 0.030 |
Why?
|
Ikaros Transcription Factor | 1 | 2017 | 233 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 594 | 0.030 |
Why?
|
Autoimmune Diseases | 1 | 2007 | 2260 | 0.030 |
Why?
|
Transcription Factor RelA | 1 | 2016 | 254 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 306 | 0.030 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 93 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2003 | 1430 | 0.030 |
Why?
|
Computational Biology | 2 | 2017 | 3562 | 0.030 |
Why?
|
Mycosis Fungoides | 1 | 2016 | 169 | 0.030 |
Why?
|
Fatigue | 2 | 2013 | 1557 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 600 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 13510 | 0.030 |
Why?
|
Diarrhea | 1 | 2021 | 1319 | 0.030 |
Why?
|
Antigens, CD1d | 2 | 2008 | 225 | 0.030 |
Why?
|
Immunity | 1 | 2000 | 1003 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2011 | 13427 | 0.030 |
Why?
|
Acute Disease | 2 | 2017 | 7245 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11229 | 0.030 |
Why?
|
Neutrophils | 2 | 2017 | 3785 | 0.030 |
Why?
|
Cohort Studies | 5 | 2019 | 41800 | 0.030 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 318 | 0.030 |
Why?
|
Pulmonary Heart Disease | 1 | 1993 | 34 | 0.030 |
Why?
|
Carcinoma | 2 | 2002 | 2340 | 0.030 |
Why?
|
Mice, Nude | 2 | 2010 | 3631 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2004 | 11119 | 0.030 |
Why?
|
Chile | 1 | 2013 | 258 | 0.030 |
Why?
|
United States | 3 | 2021 | 73180 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 716 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40266 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2012 | 351 | 0.020 |
Why?
|
Epoxy Compounds | 1 | 2012 | 137 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2016 | 1064 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20776 | 0.020 |
Why?
|
Luciferases | 1 | 2013 | 713 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 553 | 0.020 |
Why?
|
Cadherins | 1 | 2016 | 906 | 0.020 |
Why?
|
Cryopreservation | 1 | 2016 | 733 | 0.020 |
Why?
|
Israel | 1 | 2013 | 726 | 0.020 |
Why?
|
Retrospective Studies | 5 | 2024 | 81892 | 0.020 |
Why?
|
Triiodobenzoic Acids | 1 | 2011 | 123 | 0.020 |
Why?
|
Cell Culture Techniques | 3 | 2004 | 1667 | 0.020 |
Why?
|
Dioxygenases | 1 | 2013 | 352 | 0.020 |
Why?
|
Drug Resistance | 2 | 2011 | 1600 | 0.020 |
Why?
|
beta Catenin | 1 | 2016 | 1047 | 0.020 |
Why?
|
Telomerase | 1 | 2016 | 753 | 0.020 |
Why?
|
Protein Subunits | 1 | 2014 | 943 | 0.020 |
Why?
|
Adolescent | 7 | 2024 | 89247 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3214 | 0.020 |
Why?
|
Adenine | 1 | 2016 | 995 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2598 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2012 | 874 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2016 | 616 | 0.020 |
Why?
|
Observation | 1 | 2011 | 311 | 0.020 |
Why?
|
Glucocorticoid-Induced TNFR-Related Protein | 1 | 2009 | 40 | 0.020 |
Why?
|
Myelopoiesis | 1 | 2010 | 135 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2011 | 262 | 0.020 |
Why?
|
Paclitaxel | 3 | 2002 | 1735 | 0.020 |
Why?
|
Prognosis | 3 | 2018 | 30044 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8742 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3398 | 0.020 |
Why?
|
Prospective Studies | 3 | 2023 | 54950 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2012 | 664 | 0.020 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2009 | 200 | 0.020 |
Why?
|
Biopolymers | 1 | 2009 | 183 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2009 | 313 | 0.020 |
Why?
|
Neutropenia | 1 | 2013 | 893 | 0.020 |
Why?
|
Polyneuropathies | 1 | 2009 | 139 | 0.020 |
Why?
|
Arsenicals | 1 | 2008 | 117 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3588 | 0.020 |
Why?
|
Placebos | 1 | 2012 | 1668 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1609 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2059 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3811 | 0.020 |
Why?
|
Piperidines | 1 | 2016 | 1669 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2010 | 859 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2001 | 4794 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2421 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3433 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2009 | 588 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2010 | 17629 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1181 | 0.020 |
Why?
|
T-Box Domain Proteins | 1 | 2009 | 472 | 0.020 |
Why?
|
India | 1 | 2013 | 2325 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 4356 | 0.020 |
Why?
|
Oxides | 1 | 2008 | 403 | 0.020 |
Why?
|
Graft vs Tumor Effect | 1 | 2006 | 68 | 0.020 |
Why?
|
ADP Ribose Transferases | 1 | 1986 | 90 | 0.020 |
Why?
|
Exotoxins | 1 | 1986 | 123 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1993 | 957 | 0.020 |
Why?
|
HLA-DR Antigens | 2 | 1999 | 609 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 933 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2009 | 752 | 0.020 |
Why?
|
Pyrazoles | 1 | 2016 | 2029 | 0.020 |
Why?
|
Protein Multimerization | 1 | 2010 | 968 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2007 | 751 | 0.020 |
Why?
|
Thiazoles | 1 | 2012 | 1542 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5801 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2017 | 3080 | 0.010 |
Why?
|
Protein Transport | 1 | 2010 | 1956 | 0.010 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 829 | 0.010 |
Why?
|
Pneumonia | 1 | 2016 | 2163 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2011 | 3775 | 0.010 |
Why?
|
Graft Rejection | 1 | 1997 | 4492 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2006 | 719 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 4919 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 334 | 0.010 |
Why?
|
Catheterization | 2 | 2003 | 1431 | 0.010 |
Why?
|
Physician's Role | 1 | 2010 | 926 | 0.010 |
Why?
|
Virulence Factors | 1 | 1986 | 502 | 0.010 |
Why?
|
Pain | 2 | 2010 | 5100 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2007 | 1627 | 0.010 |
Why?
|
Thiotepa | 1 | 2002 | 66 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 2395 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 85 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 368 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2009 | 2004 | 0.010 |
Why?
|
NF-kappa B | 1 | 2010 | 2492 | 0.010 |
Why?
|
Plasmacytoma | 1 | 2002 | 170 | 0.010 |
Why?
|
Graft Survival | 1 | 2012 | 3888 | 0.010 |
Why?
|
Child, Preschool | 4 | 2010 | 42684 | 0.010 |
Why?
|
Cell Line | 2 | 2008 | 15603 | 0.010 |
Why?
|
Macrophages | 1 | 1996 | 5800 | 0.010 |
Why?
|
Neoplasm Metastasis | 2 | 2002 | 4926 | 0.010 |
Why?
|
Blood Cells | 1 | 2003 | 309 | 0.010 |
Why?
|
Immunization Schedule | 1 | 2002 | 228 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 1986 | 921 | 0.010 |
Why?
|
Risk Factors | 3 | 2019 | 74971 | 0.010 |
Why?
|
Immunization | 1 | 2005 | 1219 | 0.010 |
Why?
|
Microtubules | 1 | 2006 | 1062 | 0.010 |
Why?
|
Bilirubin | 1 | 2002 | 438 | 0.010 |
Why?
|
Ascites | 1 | 2002 | 338 | 0.010 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13593 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 529 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11262 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15875 | 0.010 |
Why?
|
Regeneration | 1 | 2008 | 1524 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2002 | 410 | 0.010 |
Why?
|
Mitochondria | 1 | 2012 | 3683 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2005 | 1478 | 0.010 |
Why?
|
Carboplatin | 1 | 2002 | 799 | 0.010 |
Why?
|
Pseudomonas aeruginosa | 1 | 1986 | 1276 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6673 | 0.010 |
Why?
|
Aging | 1 | 1997 | 8765 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2004 | 3102 | 0.010 |
Why?
|
Immunologic Memory | 1 | 2005 | 1378 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12469 | 0.010 |
Why?
|
Infant | 3 | 2010 | 36541 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2231 | 0.010 |
Why?
|
Progesterone | 1 | 2002 | 752 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2001 | 1616 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 2635 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1655 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2000 | 827 | 0.010 |
Why?
|
Child | 4 | 2010 | 80969 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2002 | 2227 | 0.010 |
Why?
|
Stem Cell Factor | 1 | 1996 | 194 | 0.010 |
Why?
|
HeLa Cells | 1 | 2001 | 3076 | 0.010 |
Why?
|
Estrogens | 1 | 2002 | 1537 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13677 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21545 | 0.010 |
Why?
|
DNA, Viral | 1 | 1999 | 2205 | 0.010 |
Why?
|
Biopsy | 1 | 2002 | 6805 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2010 | 26394 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12093 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 12563 | 0.000 |
Why?
|
Liver | 1 | 2002 | 7579 | 0.000 |
Why?
|
HIV Infections | 1 | 2012 | 17589 | 0.000 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 1986 | 428 | 0.000 |
Why?
|
Neutralization Tests | 1 | 1986 | 739 | 0.000 |
Why?
|
Antibody Specificity | 1 | 1986 | 1065 | 0.000 |
Why?
|
Nucleotidyltransferases | 1 | 1986 | 242 | 0.000 |
Why?
|
Pulmonary Artery | 1 | 1993 | 1945 | 0.000 |
Why?
|
Epitopes | 1 | 1986 | 2529 | 0.000 |
Why?
|